Effects of rimonabant, as monotherapy and in combination with fenofibrate or ezetimibe, on plasma adipokine levels: A pilot study

Angiology

Volumn 61, Issue 4, 2010, Pages 365-371

  Florentin, Matilda ^a   Liberopoulos, Evangelos N ^a   Tellis, Costas C ^b   Derdemezis, Christos S ^a   Elisaf, Moses ^a   Tselepis, Alexandros ^b  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Adiponectin; Ezetimibe; Fenofibrate; Leptin; Rimonabant; Visfatin

Indexed keywords

ACETYLSALICYLIC ACID; ADIPOCYTOKINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EZETIMIBE; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCHLOROTHIAZIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; RIMONABANT; TRIACYLGLYCEROL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MONOTHERAPY; OBESITY; PATIENT COMPLIANCE; PILOT STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

ADIPOKINES; ADULT; AGED; ANTILIPEMIC AGENTS; AZETIDINES; BODY MASS INDEX; DIET, REDUCING; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; FEMALE; HUMANS; MALE; MIDDLE AGED; OBESITY; PIPERIDINES; PROCETOFEN; PYRAZOLES; WEIGHT LOSS;

EID: 77952698868     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/0003319709352488     Document Type: Article

References (43)

1. Klein S., Burke LE, Bray GA, et al. Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation. 2004; 110 (18). 2952-2967.
2. Axelsson J., Heimburger O., Lindholm B., Stenvinkel P. Adipose tissue and its relation to inflammation: the role of adipokines. J Ren Nutr. 2005; 15 (1). 131-136.
3. Yamauchi T., Kamon J., Waki H., et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001; 7 (8). 941-946.
4. Li S., Shin HJ, Ding EL, van Dam RM Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA. 2009; 302 (2). 179-188.
5. Pajvani UB, Du X., Combs TP, et al. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications fpr metabolic regulation and bioactivity. J Biol Chem. 2003; 278 (11). 9073-9085.
6. Menyar A., Rizk N., Al Nabti AD, et al. Total and high molecular weight adiponectin in patients with coronary artery disease. J Cardiovasc Med (Hagerstown). 2009; 10 (4). 310-315.
7. Niswender KD, Magnuson MA Obesity and the beta cell: lessons from leptin. J Clin Invest. 2007; 117 (10). 2753-2756.
8. Munzberg H., Myers MG Jr. Molecular and anatomical determinants of central leptin resistance. Nat Neurosci. 2005; 8 (5). 566-570.
9. Sethi JK, Vidal-Puig A. Visfatin: the missing link between intraabdominal obesity and diabetes? Trends Mol Med. 2005; 11 (8). 344-347.
10. Filippatos TD, Derdemezis CS, Gazi IF, et al. Increased plasma visfatin levels in subjects with the metabolic syndrome. Eur J Clin Invest. 2008; 38 (1). 71-72.
11. Filippatos TD, Derdemezis CS, Kiortsis DN, Tselepis AD, Elisaf MS Increased plasma levels of visfatin/pre-B cell colony-enhancing factor in obese and overweight patients with metabolic syndrome. J Endocrinol Invest. 2007; 30 (4). 323-326.
12. Filippatos TD, Randeva HS, Derdemezis CS, Elisaf MS, Mikhailidis DP VISFATIN/PBEF and atherosclerosis-related diseases. Curr Vasc Pharmacol. 2010. [Epub ahead of print].
13. Pagotto U., Marsicano G., Cota D., Lutz B., Pasquali R. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev. 2006; 27 (1). 73-100.
14. Van Gaal L., Pi-Sunyer X., Despres JP, McCarthy C., Scheen A. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program. Diabetes Care. 2008; 31 (suppl 2). S229-S240.
15. Kakafika AI, Mikhailidis DP, Karagiannis A., Athyros VG The role of endocannabinoid system blockade in the treatment of the metabolic syndrome. J Clin Pharmacol. 2007; 47 (5). 642-662.
16. Press Release. The European Medicines Agency recommends suspension of the marketing authorisation of Acomplia. http://www.emea.europa.eu/. Accessed September 14, 2009.
17. Hiuge A., Tenenbaum A., Maeda N., et al. Effects of peroxisome proliferator-activated receptor ligands, bezafibrate and fenofibrate, on adiponectin level. Arterioscler Thromb Vasc Biol. 2007; 27 (3). 635-641.
18. Rosenson RS Effect of fenofibrate on adiponectin and inflammatory biomarkers in metabolic syndrome patients. Obesity (Silver Spring). 2009; 17 (3). 504-509.
19. Damci T., Tatliagac S., Osar Z., Ilkova H. Fenofibrate treatment is associated with better glycemic control and lower serum leptin and insulin levels in type 2 diabetic patients with hypertriglyceridemia. Eur J Intern Med. 2003; 14 (6). 357-360.
20. Derdemezis C., Filippatos T., Tselepis A., Mikhailidis D., Elisaf M. Effects of ezetimibe, either alone or in combination with atorvastatin, on serum visfatin levels: a pilot study. Expert Opin Pharmacother. 2008; 9 (11). 1829-1837.
21. Kostapanos MS, Derdemezis CS, Filippatos TD, et al. Effect of rosuvastatin treatment on plasma visfatin levels in patients with primary hyperlipidemia. Eur J Pharmacol. 2008; 578 (2-3). 249-252.
22. Oki K., Koide J., Nakanishi S., Nakashima R., Yamane K. Fenofibrate increases high molecular weight adiponectin in subjects with hypertriglyceridemia. Endocr J. 2007; 54 (3). 431-435.
23. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001; 285 (19). 2486-2497.
24. Zigmond AS, Snaith RP The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983; 67 (6). 361-370.
25. Kusuoka H., Hoffman JI Advice on statistical analysis for Circulation Research. Circ Res. 2002; 91 (8). 662-671.
26. Cota D., Sandoval DA, Olivieri M., et al. Food intake-independent effects of CB1 antagonism on glucose and lipid metabolism. Obesity (Silver Spring). 2009; 17 (8). 1641-1645.
27. Despres JP, Golay A., Sjostrom L. and the Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med. 2005; 353 (20). 2121-2134.
28. Gouni-Berthold I., Berthold HK, Chamberland JP, Krone W., Mantzoros CS Short-term treatment with ezetimibe, simvastatin or their combination does not alter circulating adiponectin, resistin or leptin levels in healthy men. Clin Endocrinol (Oxf). 2008; 68 (4). 536-541.
29. van Heek M., Austin TM, Farley C., Cook JA, Tetzloff GG, Davis HR Ezetimibe, a potent cholesterol absorption inhibitor, normalizes combined dyslipidemia in obese hyperinsulinemic hamsters. Diabetes. 2001; 50 (6). 1330-1335.
30. Schwartz MW, Woods SC, Porte D. Jr, Seeley RJ, Baskin DG Central nervous system control of food intake. Nature. 2000; 404 (6778). 661-671.
31. Ruige JB, Dekker JM, Blum WF, et al. Leptin and variables of body adiposity, energy balance, and insulin resistance in a population-based study. The Hoorn Study. Diabetes Care. 1999; 22 (7). 1097-1104.
32. Wallace AM, McMahon AD, Packard CJ, et al. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation. 2001; 104 (25). 3052-3056.
33. Despres JP, Ross R., Boka G., Almeras N., Lemieux I. Effect of rimonabant on the high-triglyceride/low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial. Arterioscler Thromb Vasc Biol. 2009; 29 (3). 416-423.
34. Filippatos TD, Kiortsis DN, Liberopoulos EN, Georgoula M., Mikhailidis DP, Elisaf MS Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study. Curr Med Res Opin. 2005; 21 (12). 1997-2006.
35. Nakou ES, Filippatos TD, Georgoula M., et al. The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia. Curr Med Res Opin. 2008; 24 (7). 1919-1929.
36. Florentin M., Liberopoulos EN, Filippatos TD, et al. Effect of rimonabant, micronised fenofibrate and their combination on cardiometabolic risk factors in overweight/obese patients: a pilot study. Expert Opin Pharmacother. 2008; 9 (16). 2741-2750.
37. Florentin M., Kostapanos MS, Nakou ES, Elisaf M., Liberopoulos EN Efficacy and safety of ezetimibe plus orlistat or rimonabant in statin-intolerant non-diabetic overweight/obese patients with dyslipidemia. J Cardiovasc Pharmacol Ther. 2009. [Epub ahead of print].
38. Kalogirou M., Tsimihodimos V., Gazi I., et al. Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia. Curr Med Res Opin. 2007; 23 (5). 1169-1176.
39. Choi KC, Ryu OH, Lee KW, et al. Effect of PPAR-alpha and-gamma agonist on the expression of visfatin, adiponectin, and TNF-alpha in visceral fat of OLETF rats. Biochem Biophys Res Commun. 2005; 336 (3). 747-753.
40. Koh KK, Han SH, Quon MJ, Yeal Ahn J., Shin EK Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia. Diabetes Care. 2005; 28 (6). 1419-1424.
41. Hara K., Horikoshi M., Yamauchi T., et al. Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care. 2006; 29 (6). 1357-1362.
42. Liu SW, Qiao SB, Yuan JS, Liu DQ Association of plasma visfatin levels with inflammation, atherosclerosis and acute coronary syndromes (ACS) in humans. Clin Endocrinol (Oxf). 2009; 71 (2). 202-207.
43. Dahl TB, Yndestad A., Skjelland M., et al. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation. 2007; 115 (8). 972-980.